On June 25, 2021, Gamida Cell Ltd. announced that Dr. Tracey Lodie, the company’s chief scientific officer, has tendered her resignation, effective on July 9, 2021, to pursue another opportunity at a private cell therapy company outside the area of oncology. Dr. Lodie will remain engaged with Gamida Cell by serving as a scientific advisor and consultant to the company to see both omidubicel and GDA-201 through key regulatory and development milestones.